Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- FDA (2)
- ANDA (1)
- Abbreviated New Drug Application (1)
- Albert Gonzalez (1)
- Andrx Pharmaceuticals Inc. v. Biovail Corp (1)
-
- Ayers (1)
- BJS (1)
- Bureau of Justice Statistics of the Department of Justice (1)
- CDER (1)
- Center for Drug Evaluation and Research (1)
- ChoicePoint (1)
- Drug Price Competition and Patent Term Restoration Act (1)
- Eli Lilly v. Barr Laboratories (1)
- Eli Lilly v. Teva (1)
- Eli Lilly v. Zenith Goldline (1)
- FTC (1)
- Federal Trade Commission (1)
- Food and Drug Administration (1)
- Giordano v. Wachovia Securities (1)
- Hatch-Waxman Act (1)
- ITRC (1)
- Identity Theft Resource Center (1)
- James K. Baker (1)
- Marshalls (1)
- NNI (1)
- NTIG (1)
- Nanotechnology Interest Group (1)
- National Nanotechnology Initiative (1)
- Novartis v. Dr. Reddy’s Laboratories (1)
- Quantum Dots (1)
Articles 1 - 3 of 3
Full-Text Articles in Law
“Medical” Monitoring For Non-Medical Harms: Evaluating The Reasonable Necessity Of Measures To Avoid Identity Fraud After A Data Breach, James Graves
Richmond Journal of Law & Technology
In July 2005, “reformed” hacker Albert Gonzalez noticed an insecure wireless network at a Marshalls department store in Miami. After exploiting the vulnerability, Gonzalez and his accomplices installed programs that captured credit card numbers. They stored the credit card numbers on servers in Latvia and Ukraine, created ATM cards using some of the numbers, and used those cards to withdraw hundreds of thousands of dollars in cash. Fifteen months later, Marshalls’ parent company, TJX, announced that forty-five million of its customers’ credit card numbers had been exposed to the thieves.
The Regulation Of Nanomedicine: Will The Existing Regulatory Scheme Of The Fda Suffice?, Shanna Harris
The Regulation Of Nanomedicine: Will The Existing Regulatory Scheme Of The Fda Suffice?, Shanna Harris
Richmond Journal of Law & Technology
Nanotechnology is the science and technology of manipulating molecules and atoms at the molecular level to create devices with new molecular properties, organizations and functions.1 Devices such as new computers that are billions of times more powerful than any currently available2 and boxes the size of sugar cubes that can hold the entire content of the Library of Congress are examples of the power of nanotechnology.
Will The Federal Circuit’S Eli Lilly V. Teva Decision Lead To Efforts To Abuse The Modification Provision Of The Hatch-Waxman Act?, Claire K. Comfort
Will The Federal Circuit’S Eli Lilly V. Teva Decision Lead To Efforts To Abuse The Modification Provision Of The Hatch-Waxman Act?, Claire K. Comfort
Richmond Journal of Law & Technology
The Hatch-Waxman Act provides a mandatory thirty-month stay on the Food and Drug Administration’s (FDA) approval of an Abbreviated New Drug Application (ANDA) when a patent infringement suit is filed. The Act includes a provision for a district court to shorten or extend the Act’s thirty-month stay on FDA approval if “either party to the action failed to reasonably cooperate in expediting the action”